The global mrna vaccines and therapeutics market was valued at USD 12.85 billion in 2025. The market is projected to grow from USD 14.58 billion in 2026 to USD 34.19 billion by 2034, exhibiting a compound annual growth rate of 11.24% during the forecast period. Contrive Datum Insights presents this information in its report titled "Mrna Vaccines And Therapeutics Market Size, Share & Industry Analysis, By Type (Standardization Of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine, Other), Application (Hospital, Clinic, Other), Treatment type (Monoclonal Antibody, Gene Therapy, Cell Therapy, Others), Technology (Conventional mRNA, Self-Amplifying mRNA, Circular and Other Next-Generation mRNA), Delivery system (Lipid Nanoparticle (LNP)-Based, Polymer-Based, Peptide-Based, Other Delivery Systems), and Regional Forecast, 2026-2034".
This market covers products that use synthetic messenger RNA to instruct a patient's own cells to produce a target protein, either to trigger an immune response against an infectious agent or a tumor antigen, or to supply an antibody, gene or cell-therapy function the patient's own biology cannot. Forms include prophylactic infectious-disease vaccines, standardized and individualized cancer vaccines, and mRNA-encoded antibody, gene-therapy and cell-therapy products, most delivered through a lipid nanoparticle or comparable formulation. Buyers are national immunization programs, hospital and specialty oncology networks, and biopharmaceutical developers licensing the underlying delivery platform.
Oncology pipeline progress toward approved mRNA cancer vaccines
Oncology pipeline progress toward approved mRNA cancer vaccines is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.24% a year, the type lines exposed to it move fastest: Individualized Cancer Treatment MRNA Vaccine compounds at 17.52%, taking its share of revenue from 9% to 15% and its value from USD 1.16 billion to USD 5.13 billion.
A more favourable outcome is possible. If bull case assumes faster-than-expected approval of therapeutic cancer and non-COVID infectious-disease mRNA vaccine candidates, sustained manufacturing-capacity investment, and no major delivery-platform safety setback, 2034 revenue reaches USD 43.26 billion instead of the USD 34.19 billion the base case carries.
On the downside, bear case assumes slower trial-to-approval progress for therapeutic mRNA vaccines, tighter reimbursement following the wind-down of pandemic-era emergency funding, and manufacturing capacity growing more slowly than planned, which would hold 2034 revenue to USD 25.67 billion. Infection Prevention MRNA Vaccine, which carries 52% of 2025 revenue, already grows at only 5.26% against the market's 11.24%, so the largest part of the base is also its slowest.
The Competitive Split Runs by Type
Competition in the global mrna vaccines and therapeutics market runs along the type axis, not the regional one. Infection Prevention MRNA Vaccine holds 52% of 2025 revenue at USD 6.68 billion and remains the largest line through 2034 at 32%, making it the position hardest for a challenger to take. Individualized Cancer Treatment MRNA Vaccine, growing at 17.52%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 12.85 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Application | Hospital | 58% · USD 7.45 billion | Clinic 12.97% |
| Treatment type | Monoclonal Antibody | 35% · USD 4.5 billion | Cell Therapy 14.5% |
| Technology | Conventional mRNA | 78% · USD 10.02 billion | Circular and Other Next-Generation mRNA 20.41% |
| Delivery system | Lipid Nanoparticle (LNP)-Based | 84% · USD 10.79 billion | Peptide-Based 17.54% |
- Regionally, the lead sits with North America: 46% of 2025 global revenue, USD 5.92 billion rising to USD 14.36 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 19% in 2025 to 24% in 2034, with revenue growing from USD 2.44 billion to USD 8.21 billion.
- Middle East and Africa stays the smallest contributor across the period: 4% of revenue in 2025 and 4% in 2034.
- By type, the largest line in 2025 was Infection Prevention MRNA Vaccine, at 52% of revenue and USD 6.68 billion.
- The fastest type line is Individualized Cancer Treatment MRNA Vaccine, forecast to compound at 17.52% through the period.
- The United States is the largest single country market at USD 5.33 billion in 2025, 41.48% of global revenue.
The report segments the market across five axes; by type, and by application, treatment type, technology and delivery system; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 25.67 billion and USD 43.26 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.